Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for the HDV market.

Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from GvHD in patients following a kidney transplant.

Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102.

Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 in PD patients with a pathogenic mutation in GBA-PD.

Lilly’s weight loss pill gained approval in April 2026, around three months after Novo Nordisk gained the same accolade for oral Wegovy.

Lilly's retatrutide may have the best weight loss efficacy so far, but analysts are concerned around its tolerability compared with tirzepatide.

Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC.

Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating BIIB122 for early-stage Parkinson’s disease.

An upcoming conference will investigate the latest trends in the medical devices and medtech clinical trials industry with a focus on navigating recent regulatory changes. The Out ...

The rise in infectious disease outbreaks globally is being driven by several factors, including increased global travel and urbanisation.

IgA nephropathy involves pathogenic IgA-containing immune complexes depositing in kidneys. Credit: superbeststock / Shutterstock.com. Jade Biosciences has dosed the first participant in its Phase II ...